GlassScriptPhysician profile
Michael Dennis Domash
NPI 1083793905
$3,274.31
in general payments reported to CMS, 2019-2025
25 companies · $700 in 2025
The $700 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $324 · 2021: $365 · 2022: $604 · 2023: $768 · 2024: $293 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $535.24 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $387.64 | 2020-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $315.13 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $259.57 | 2019-2025 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $259.07 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $239.33 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $161.17 | 2020-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.55 | 2021-2023 | |
| Alkermes, INC. | $150.48 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $122.68 | 2019-2023 | Spravato |
| Lundbeck LLC | $114.75 | 2019-2023 | Rexulti |
| Corium, LLC | $94.92 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $91.69 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $73.89 | 2022 | |
| Supernus Pharmaceuticals, INC. | $55.17 | 2022-2025 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $48.92 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $29.14 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $27.77 | 2025 | Cobenfy |
| Bausch Health US, LLC | $24.87 | 2022 | |
| Allergan, INC. | $24.33 | 2020 | |
| Vertical Pharmaceuticals, LLC | $24.07 | 2019 | |
| Eisai INC. | $22.31 | 2020 | |
| Idorsia Pharmaceuticals US INC | $20.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Domash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.